Video
Dr. Albala on the recent CMS change for Rezum water vapor therapy
Author(s):
“I think this really now suggests that Rezum is a financially viable procedure across these different treatment settings…the reimbursement now is really quite favorable,” says David M. Albala, MD.
Video Player is loading.
In this video, David M. Albala, MD, discusses the recent change made by the Centers for Medicare & Medicaid Services regarding Rezum water vapor therapy. This new change allows for more financial coverage for patients with benign prostatic hyperplasia (BPH) who seek this treatment. Albala is a urologist at Associate Medical Professionals and chief of urology at Crouse Hospital in Syracuse, New York.
Related Videos
Study data point to gender disparities in oncology research citations
Matthew Galsky, MD, on patient selection for perioperative durvalumab/chemo in MIBC
Ekene Enemchukwu, MD, on guideline-associated trends in OAB therapy use
Nitin Yerram, MD, highlights trial of 177Lu-PSMA-617 in localized prostate cancer
Karyn S. Eilber, MD, on patient counseling for onabotA treatment for OAB
Optimizing onabotA for OAB: What are some common misconceptions?
Ian Metzler, MD, on the role for telemedicine, digital health tools in stone disease
BPH Management: Patient Outcome Evolution
Nitin Yerram, MD, highlights new resource center for patients with renal cell carcinoma
Perry Xu, MD, discusses PCNL’s role in the age of minimally invasive URS
Related Content
